Literature DB >> 30180779

Clinical Outcomes from a Multi-Center Study of Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury.

Allan D Levi1, Kim D Anderson1, David O Okonkwo2, Paul Park3, Thomas N Bryce4, Shekar N Kurpad5, Bizhan Aarabi6, Jane Hsieh7, Katie Gant1.   

Abstract

Human neural stem cell transplantation (HuCNS-SC®) is a promising central nervous system (CNS) tissue repair strategy in patients with stable neurological deficits from chronic spinal cord injury (SCI). These immature human neural cells have been demonstrated to survive when transplanted in vivo, extend neural processes, form synaptic contacts, and improve functional outcomes after experimental SCI. A phase II single blind, randomized proof-of-concept study of the safety and efficacy of HuCNS-SC transplantation into the cervical spinal cord was undertaken in patients with chronic C5-7 tetraplegia, 4-24 months post-injury. In Cohort I (n = 6) dose escalation from 15,000,000 to 40,000,000 cells was performed to determine the optimum dose. In Cohort II an additional six participants were transplanted at target dose (40,000,000) and compared with four untreated controls. Within the transplant group, there were nine American Spinal Injury Association Impairment Scale (AIS) B and three AIS A participants with a median age at transplant of 28 years with an average time to transplant post-injury of 1 year. Immunosuppression was continued for 6 months post-transplant, and immunosuppressive blood levels of tacrolimus were achieved and well tolerated. At 1 year post-transplantation, there was no evidence of additional spinal cord damage, new lesions, or syrinx formation on magnetic resonance (MR) imaging. In summary, the incremental dose escalation design established surgical safety, tolerability, and feasibility in Cohort I. Interim analysis of Cohorts I and II demonstrated a trend toward Upper Extremity Motor Score (UEMS) and Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) motor gains in the treated participants, but at a magnitude below the required clinical efficacy threshold set by the sponsor to support further development resulting in early study termination.

Entities:  

Keywords:  SCI; human; stem cells; tetraplegia; transplantation

Year:  2018        PMID: 30180779     DOI: 10.1089/neu.2018.5843

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  29 in total

Review 1.  The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.

Authors:  Andrew R Blight; Jane Hsieh; Armin Curt; James W Fawcett; James D Guest; Naomi Kleitman; Shekar N Kurpad; Brian K Kwon; Daniel P Lammertse; Norbert Weidner; John D Steeves
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

Review 2.  Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system.

Authors:  James D Guest; John D Steeves; M J Mulcahey; Linda A T Jones; Frank Rockhold; Rϋediger Rupp; John L K Kramer; Steven Kirshblum; Andrew Blight; Daniel Lammertse
Journal:  Spinal Cord       Date:  2020-09-16       Impact factor: 2.772

3.  Study of the Diffusion Tensor Imaging for Preclinical Therapeutic Efficacy of Umbilical Cord Mesenchymal Stem Cell Transplantation in the Treatment of Spinal Cord Injury.

Authors:  Ying Zhao; Liqing Yao; Lijuan Ao; Jibing Ou; Ying He; Yunyun Shang
Journal:  Int J Gen Med       Date:  2021-12-13

Review 4.  Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials.

Authors:  Emmanouil I Damianakis; Ioannis S Benetos; Dimitrios Stergios Evangelopoulos; Aikaterini Kotroni; John Vlamis; Spyridon G Pneumaticos
Journal:  Cureus       Date:  2022-04-28

5.  Current barriers and ethical considerations for clinical implementation of epidural stimulation for functional improvement after spinal cord injury.

Authors:  Ryan Solinsky; Laura Specker-Sullivan; Anna Wexler
Journal:  J Spinal Cord Med       Date:  2019-09-24       Impact factor: 1.985

Review 6.  Electroactive Scaffolds to Improve Neural Stem Cell Therapy for Spinal Cord Injury.

Authors:  Anthea R Mutepfa; John G Hardy; Christopher F Adams
Journal:  Front Med Technol       Date:  2022-02-22

7.  IL-10 lentivirus-laden hydrogel tubes increase spinal progenitor survival and neuronal differentiation after spinal cord injury.

Authors:  Andrew J Ciciriello; Dominique R Smith; Mary K Munsell; Sydney J Boyd; Lonnie D Shea; Courtney M Dumont
Journal:  Biotechnol Bioeng       Date:  2021-04-23       Impact factor: 4.395

8.  Phase 1 Safety Trial of Autologous Human Schwann Cell Transplantation in Chronic Spinal Cord Injury.

Authors:  Katie L Gant; James D Guest; Anne E Palermo; Aditya Vedantam; George Jimsheleishvili; Mary Bartlett Bunge; Adriana E Brooks; Kim D Anderson; Christine K Thomas; Andrea J Santamaria; Monica A Perez; Rosie Curiel; Mark S Nash; Efrat Saraf-Lavi; Damien D Pearse; Eva Widerström-Noga; Aisha Khan; W Dalton Dietrich; Allan D Levi
Journal:  J Neurotrauma       Date:  2021-05-03       Impact factor: 4.869

9.  Acute Implantation of Aligned Hydrogel Tubes Supports Delayed Spinal Progenitor Implantation.

Authors:  Andrew J Ciciriello; Dominique R Smith; Mary K Munsell; Sydney J Boyd; Lonnie D Shea; Courtney M Dumont
Journal:  ACS Biomater Sci Eng       Date:  2020-09-14

10.  Efficacy of neural stem cell transplantation for the treatment of patients with spinal cord injury: A protocol of systematic review and meta-analysis.

Authors:  Hua-Yu Tang; Yu-Zhi Li; Zhao-Chen Tang; Lu-Yao Wang; Tian-Shu Wang; Fernando Araujo
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.